Definitive Healthcare Corp.

Definitive Healthcare announced the grant of inducement awards to Srinivas Attipalli, its new SVP and Head of AI & Data - Product. Mr. Attipalli received 1,063,830 time-based restricted stock units (RSUs), effective July 24, 2026. These awards are part of the company's 2023 Inducement Plan and will vest over time, with 25% vesting on June 1, 2027, and the remainder in quarterly installments.

Definitive Healthcare Corp. received a notice from Nasdaq on June 18, 2026, indicating non-compliance with the minimum bid price requirement. The company's common stock traded below $1.00 for 30 consecutive business days. Definitive Healthcare has a 180-calendar-day period, until December 15, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of ten consecutive business days. The company intends to monitor its stock price and consider options, including a reverse stock split, to address the deficiency.

Definitive Healthcare announced several product enhancements to provide a clearer view of the healthcare ecosystem and accelerate market intelligence. These updates include expanded Atlas All-Payor Claims coverage with new data sources and enhanced diagnosis detail. The company also introduced a new integration for HubSpot CRM and direct access to HCP data within Salesforce. Additionally, new AI search capabilities are being rolled out for Monocl ExpertInsight and View Suite products, enabling intuitive, conversational queries. These enhancements aim to strengthen data foundation and improve access to insights for customers across sales, marketing, and strategy.

Definitive Healthcare Corp. reported a significant net loss of $(192.35) million for the first quarter of 2026, primarily driven by a non-cash goodwill impairment charge of $197.22 million. Revenue for the quarter also saw a decline to $55.93 million compared to the prior year. The company's total assets and equity decreased substantially from the end of 2025.

Definitive Healthcare reported Q1 2026 financial results, with revenue at $55.9 million, a 6% decrease year-over-year. The company posted a net loss of $(192.4) million, significantly impacted by $197.2 million in goodwill impairment charges. Despite the GAAP loss, adjusted net income increased to $8.5 million and adjusted EBITDA rose to $15.3 million. The company provided Q2 2026 revenue guidance of $55.0-$56.0 million and full-year 2026 revenue guidance of $220.0-$226.0 million, with the CEO noting a solid start and progress on strategic pillars.

Definitive Healthcare Corp. announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, after the market closes. The company will host a conference call and webcast at 5:00 PM ET to discuss the results. Investors can access the live audio webcast via the company's Investor Relations website or by dialing in, with a replay available until June 6, 2026.

Definitive Healthcare Corp. (DH) announced the termination of its Nominating Agreement with SE VII DHC AIV, L.P. ("Spectrum"), effective April 3, 2026. This agreement, originally dated September 17, 2021, granted Spectrum the right to designate one director to the Company's board, provided Spectrum and its affiliates beneficially owned at least 5% of the outstanding common stock. The termination follows the resignation of Jeff Haywood, the Spectrum Designee, from the board of directors on March 30, 2026. This move permanently and irrevocably ends Spectrum's contractual right to board representation.

Jeff Haywood resigned from Definitive Healthcare's Board of Directors and the Human Capital Management and Compensation Committee, effective immediately. The board size was reduced from 9 to 8 members, and the compensation committee size was reduced from 3 to 2 members. The resignation was not due to any disagreements with the company.